Pharmaceuticals
Altos Biologics, a Subsidiary of Alteogen, Completed Patient Enrollment in Global Phase 3 Clinical Trial of Eylea® Biosimilar in Neovascular Age-related Macular Degeneration
* Altos Biologics, a subsidiary of Alteogen, is actively engaged in Eylea® Biosimilar (ALT-L9) clinical development and licensing-out discussions. * Early 2024 projected for Phase 3 completion and product launch in Europe expected after obtaining approval in the first half of 2025. DAEJEON, So...
2023-02-22 22:00
2279
150th Anniversary of Dr. Hansen's Discovery of M. leprae Is Opportunity to Examine Past, Present and Future of Leprosy
TOKYO, Feb. 22, 2023 /PRNewswire/ -- The University of Bergen, Norway and Sasakawa Leprosy (Hansen's Disease) Initiative will hold an event inBergen on Feb. 28, 2023, to mark the 150th anniversary of Dr. Gerhard Armauer Hansen's discovery of the leprosy bacillus,M. leprae, in 1873. On the same da...
2023-02-22 22:00
2104
GenScript ProBio and RVAC Medicines Announce Strategic Partnership for GMP Plasmid DNA Manufacturing for mRNA COVID-19 Vaccine Candidate
PISCATAWAY, N.J. and SINGAPORE, Feb. 22, 2023 /PRNewswire/ -- GenScript ProBio, a leading global Contract Development and Manufacturing Organization (CDMO), and RVAC Medicines Pte. Ltd., a biotechnology company focusing on the development and commercialization of messenger RNA (mRNA) therapeu...
2023-02-22 21:00
2533
Fapon Biopharma's Anti-CD47 Antibody FP002 Earns IND Approval from FDA
SHENZHEN, China, Feb. 22, 2023 /PRNewswire/ -- Fapon Biopharma, an innovative biotech company, announced today that its Investigational New Drug (IND) application of FP002, an anti-CD47 monoclonal antibody drug candidate, has been approved by FDA for clinical trials. FP002 is a humanized anti-CD...
2023-02-22 20:17
1895
Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON
WUHAN, China and SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today thatthe last patient has been enrolled in the Phase III clinical trial for the treatment of Leber hereditary optic neuropathy (LHON) inChina. It marks the completion of patient enr...
2023-02-21 21:30
2621
NMPA accepted the registration applications for Uro-G and Uro-3500
SHANGHAI, Feb. 21, 2023 /PRNewswire/ -- Asieris Pharmaceuticals (688176), a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the registration applications for ...
2023-02-21 17:46
1932
RVAC Medicines Secures HSA Approval to Initiate Phase 1B Clinical Trial in Singapore
SINGAPORE, Feb. 20, 2023 /PRNewswire/ -- RVAC Medicines Pte. Ltd. (RVAC), a messenger RNA (mRNA) technology platform company, announced today that it has secured the approval from the Health Sciences Authority (HSA) to initiate Phase 1B clinical trial in Singapore to evaluate the safety and immuno...
2023-02-21 10:00
1933
Bridge Biotherapeutics Presents Phase 2a Clinical Trial Results For BBT-401, a Drug Candidate to Treat Ulcerative Colitis
* BBT-401 meets safety endpoints achieved in previous clinical studies * The drug candidate did not achieve an improved clinical response compared to the placebo study group * 54.5% of the treatment cohort exhibited a valid treatment response to orally administered BBT-401 SEONGNAM, South Ko...
2023-02-21 07:00
1769
EDAN Pictured the Long-Term Regional Development Plans with the Minister Counselor of the Chinese Embassy in Kenya
NAIROBI, Kenya, Feb. 20, 2023 /PRNewswire/ -- Minister Counselor of the Chinese Embassy inKenya, Yijun Zhang held a meeting on February 7, 2023 with Alex You, Global Marketing & Strategic Operations Director, andVincent Bi, Customer Service & Healthcare Informatics Director ofEdan Instruments, In...
2023-02-21 00:15
2455
Celltrion and LISCure Biosciences announce strategic collaboration to develop novel microbiome treatment for Parkinson's disease
* Co-research and co-development of novel microbiome therapeutics * Discovery of new candidates to meet high unmet medical needs in Parkinson's disease SEOUL, South Korea, Feb. 20, 2023 /PRNewswire/ -- LISCure Biosciences Inc., a clinical-stage biotech developing advanced microbiome technology...
2023-02-20 22:00
2050
Daewoong Pharmaceutical Reaches Sales of KRW 1.16 Trillion in 2022, Fexuclue Leads The Highest Revenue
- Hitting a record high sale with business profits of KRW 106 billion and net profits ofKRW 80.1 billion according to the accounting of 2022 - Not only stable positioning of Fexuclue but also achievement obtaining a permit of new medicine for Envlo SEOUL, South Korea, Feb. 19, 2023 /PRNewswire/ ...
2023-02-20 12:29
1938
GC Biopharma Receives WHO Pre-Qualification for BARYCELA
YONGIN, South Korea, Feb. 19, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that the World Health Organization (WHO) has granted prequalification for BARYCELA, GC Biopharma's varicella vaccine. WHO prequalificatio...
2023-02-20 09:38
1975
Qilian International Holding Group Ltd Declares Special Cash Dividends to Shareholders
JIUQUAN, China, Feb. 16, 2023 /PRNewswire/ -- Qilian International Holding Group Ltd (the "Company" or Nasdaq: QLI), aChina-based pharmaceutical and chemical products manufacturer, announced today that the Company has declared a special one-time cash dividend of$0.05 per ordinary share, payable i...
2023-02-17 05:30
3392
GLOBAL SARCOMA THERAPY NOW APPROVED FOR NEW ZEALAND PATIENTS
* Globally regarded soft-tissue sarcoma therapy has been approved by Medsafe forNew Zealand patients * YONDELIS® (trabectedin) demonstrates 45% reduction in risk of disease progression or death versus dacarbazine[1] SINGAPORE and AUCKLAND, New Zealand, Feb. 16, 2023 /PRNewswire/ -- Independen...
2023-02-17 03:00
2329
111, Inc. Hosts Hua Medicine Launches First Official Flagship Store
SHANGHAI, Feb. 16, 2023 /PRNewswire/ -- On February 15, 2023, 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company inChina, announced that during the HuaTangNing® Market Launch for Innovative Commerce Cooperation, Dr.Yu Gang, Co-founder and Executive...
2023-02-16 13:33
2072
Randomized Controlled Trial Backs Clinical Efficacy of Lunit AI for Chest X-Ray
* First-ever randomized controlled trial regarding deep learning-based AI in radiology provides strong evidence for the clinical value of AI * Large-scale study with 10,476 patients published in Radiology, the top journal in radiology SEOUL, South Korea, Feb. 13, 2023 /PRNewswire/ -- Findings ...
2023-02-13 21:00
1883
B dot Medical to Install Ultra-compact Proton Therapy System at Thammasat University in Thailand
- Responding to Growing Needs for Urban-type Proton Therapy in Thailand - TOKYO and BANGKOK, Feb. 13, 2023 /PRNewswire/ -- B dot Medical Inc. and Thammasat University, a leading national university in Thailand, have signed a memorandum of understanding to install the ultra-compact proton therapy ...
2023-02-13 14:00
2234
HanAll Biopharma Invests in Interon to Seek Collaboration Opportunities
* HanAll will invest in Interon Laboratories, a preclinical-stage biotechnology company focused on treating complex neurological disorders * Interon is developing a new category of immunotherapy for people with neurological and immune disorders starting with autism spectrum disorder SEOUL, So...
2023-02-10 20:00
2998
Nona Biosciences Enters into HCAb Based Antibody Discovery Collaboration Agreement with Mythic Therapeutics
CAMBRIDGE, Mass., Feb. 10, 2023 /PRNewswire/ -- Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Limited committed to cutting edge technology innovations, and providing a total solution from "Idea to IND" ("I to ITM"), today announced that it has entered into a collaboration agreement ...
2023-02-10 13:00
2173
US based COBRA diagnostic prostate cancer trial reaches recruitment target
SYDNEY, Feb. 9, 2023 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce its diagnostic 64Cu SAR-...
2023-02-09 22:03
2319
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6801
